{"links":{"html":"https://www.erudio.com/reports/surtime-nct01099423","json":"https://www.erudio.com/reports/surtime-nct01099423.json","markdown":"https://www.erudio.com/reports/surtime-nct01099423.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"surtime-01099423"}},"request":"https://www.erudio.com/contact?report=surtime-01099423"},"offer":{"cited_commentary_sources":32,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a licence key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, to join with NPI-keyed systems such as a CRM. Every report already names and describes its speakers.","available_with":"12-month updates","cap_usd":1250,"identity_verified_people":53,"optional":true,"price_per_verified_person_usd":15,"price_usd":795,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One licence key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_tools":["create_order","get_order","recover_key"],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"surtime-nct01099423"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the licence key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=surtime-01099423","people":"Tom and Audun, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/surtime-nct01099423","renewal":"Subscriptions are prepaid and do not renew automatically.","terms":"https://www.erudio.com/terms"},"size":"standard","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-08T02:08:11.487997Z","notify_subscribers":false,"status":"corrected","summary":"taxonomy mapping corrected"},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":12,"no_commentary_found":0},"aspects":[{"claim_count":13,"coverage":"discussed","id":"A1","source_count":7,"title":"Immediate versus systemic-first nephrectomy"},{"claim_count":17,"coverage":"discussed","id":"A2","source_count":7,"title":"Outcome interpretation, endpoints and accrual"},{"claim_count":18,"coverage":"discussed","id":"A3","source_count":5,"title":"Selection by response and timing of consolidation"},{"claim_count":31,"coverage":"discussed","id":"A4","source_count":8,"title":"Risk scores, fitness, metastatic distribution and histology"},{"claim_count":18,"coverage":"discussed","id":"A5","source_count":5,"title":"Residual primary, renal preservation and postoperative treatment"},{"claim_count":25,"coverage":"discussed","id":"A6","source_count":10,"title":"Observational benefit, confounding and time-related bias"},{"claim_count":11,"coverage":"discussed","id":"A7","source_count":3,"title":"Local symptoms, thrombus and urgent-treatment exceptions"},{"claim_count":19,"coverage":"discussed","id":"A8","source_count":4,"title":"Perioperative holds, wound healing and operative complexity"},{"claim_count":32,"coverage":"discussed","id":"A9","source_count":9,"title":"Modern regimens, access, toxicity and surveillance alternatives"},{"claim_count":33,"coverage":"discussed","id":"A10","source_count":3,"title":"Primary-tumor radiation as an alternative cytoreductive approach"},{"claim_count":16,"coverage":"discussed","id":"A11","source_count":8,"title":"Mechanisms, biomarkers and tissue acquisition"},{"claim_count":18,"coverage":"discussed","id":"A12","source_count":7,"title":"Patient preference, preparation and multidisciplinary care"}],"counts":{"cited_sources":32,"claims_by_expression_type":{"comparison":60,"experience":25,"interpretation":75,"opinion":65,"primary_context":3,"question":49,"restatement":100,"uncertainty":34,"unspecified":16},"claims_by_kind":{"attributed_opinion":20,"counterview":9,"interpretation":39,"limitation":28,"source_observation":331},"evidence_units":308,"findings":13,"people_cited":38,"people_identity_verified":53,"people_total":65,"screened_sources":34,"verified_claims":427},"depth":"rich","depth_rule":"thin if verified claims <30, findings <5, or cited sources <10; rich if verified claims >=100, findings >=8, and cited sources >=30; otherwise standard","findings_index":[{"id":"F1","title":"Systemic-first treatment is a selection strategy, not a universal prohibition on nephrectomy"},{"id":"F2","title":"Deferred nephrectomy has materially different timing interpretations"},{"id":"F3","title":"SURTIME is recalled as favorable, null or inconclusive, with substantial methodological caution"},{"id":"F4","title":"Selection extends beyond risk labels, with unresolved subgroup and histology boundaries"},{"id":"F5","title":"Residual renal lesions and treatment-free goals leave the later-surgery decision unresolved"},{"id":"F6","title":"Favorable observational signals provoke a dispute about causal interpretation"},{"id":"F7","title":"Symptoms and tumor thrombus are consequential exceptions, but not agreed automatic surgical indications"},{"id":"F8","title":"Perioperative management is more definite for TKIs than for immunotherapy, while surgical complexity remains debated"},{"id":"F9","title":"Modern systemic choices change the application of sunitinib-era sequencing evidence"},{"id":"F10","title":"Neither surgery nor immediate systemic treatment is inevitable for every metastatic presentation"},{"id":"F11","title":"Primary-tumor radiation remains a separate approach; later Cytoshrink commentary limits the earlier rationale"},{"id":"F12","title":"Biological explanations and biomarkers are attractive but remain hypotheses or research tools"},{"id":"F13","title":"Patient preferences, preparation and experienced multidisciplinary care are part of the decision itself"}],"medical_affairs_question":"How can scientific exchange distinguish systemic-first sequencing for patients who need treatment from a blanket no-nephrectomy message?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Systemic-first treatment is a selection strategy, not a universal prohibition on nephrectomy"},{"id":"section-2","level":2,"title":"Deferred nephrectomy has materially different timing interpretations"},{"id":"section-3","level":2,"title":"SURTIME is recalled as favorable, null or inconclusive, with substantial methodological caution"},{"id":"section-4","level":2,"title":"Selection extends beyond risk labels, with unresolved subgroup and histology boundaries"},{"id":"section-5","level":2,"title":"Residual renal lesions and treatment-free goals leave the later-surgery decision unresolved"},{"id":"section-6","level":2,"title":"Favorable observational signals provoke a dispute about causal interpretation"},{"id":"section-7","level":2,"title":"Symptoms and tumor thrombus are consequential exceptions, but not agreed automatic surgical indications"},{"id":"section-8","level":2,"title":"Perioperative management is more definite for TKIs than for immunotherapy, while surgical complexity remains debated"},{"id":"section-9","level":2,"title":"Modern systemic choices change the application of sunitinib-era sequencing evidence"},{"id":"section-10","level":2,"title":"Neither surgery nor immediate systemic treatment is inevitable for every metastatic presentation"},{"id":"section-11","level":2,"title":"Radiation is raised as a different local-cytoreduction approach, not evidence that nephrectomy is unnecessary"},{"id":"section-12","level":2,"title":"Biological explanations and biomarkers are attractive but remain hypotheses or research tools"},{"id":"section-13","level":2,"title":"Patient preferences, preparation and experienced multidisciplinary care are part of the decision itself"},{"id":"section-14","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, single group, phase3"},"identity":{"accepted_at":"2026-10-08T02:08:11.487997Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-07T22:54:07Z","record_hash":"11ff6719d248290d1a21d2678a124b348dd6de3b03339808c0e74fbd37878768","release_hash":"1953726f4d49fe979f722e8ee5e35737fb8e098a6c579d12e5992947a45c1ba3","report_id":"erudio-nct01099423","run_id":"adfa342c-3177-48b1-9811-8ef45955f498","schema_version":"5.0","slug":"surtime-01099423","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"SURTIME frames the question of whether patients whose kidney cancer has spread at diagnosis should have kidney surgery first or start systemic treatment before deciding on later surgery. Clinicians discuss trial endpoints and enrollment, patient selection by response and risk, surgical timing, residual renal lesions, postoperative therapy, and applicability to modern drug combinations. Further topics include local symptoms, operative risks, observation and radiation alternatives, biomarkers, treatment access, patient priorities and multidisciplinary care.","meta_description":"34 HCP sources screened · 427 verified claims from 32 sources · 13 findings. Updated 2026-10-08.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-7ad979a23d3bcd23abbf"],"id":"F3","paraphrase":"A podcast speaker asked what limitations, apart from sample size, matter when interpreting SURTIME’s immediate-versus-deferred nephrectomy comparison in intermediate-risk, clear-cell metastatic renal cancer.","source_channel":"podcast","source_date":"2024-02-18","title":"SURTIME is recalled as favorable, null or inconclusive, with substantial methodological caution"},{"cited_claim_ids":["claim-af1a92292e118438013d"],"id":"F5","paraphrase":"A podcast speaker asked whether removing a residual kidney lesion makes sense when long-term TKI therapy might be stopped or paused because of side effects or patient choice. The speaker also asked about kidney-sparing surgery for a remaining cystic lesion after treatment.","source_channel":"podcast","source_date":"2025-06-11","title":"Residual renal lesions and treatment-free goals leave the later-surgery decision unresolved"}]},"publication":{"approved_at":"2026-10-07T22:54:07Z","approved_by":"Audun Utengen","corrections":[{"affected_ids":[],"date":"2026-10-08T20:30:00Z","summary":"A speaker card linked to the wrong physician was removed; duplicate cards for the same person were combined"},{"affected_ids":[],"date":"2026-10-09T20:08:00Z","summary":"taxonomy mapping corrected"}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"1.0","scope_and_limits":{"commentary_scope":{"basis":"Reviewed retained sources only; not all HCPs or all public discussion.","empty_source_ids":[],"has_known_gaps":true,"held_out_finds":11,"retrieval_gaps":["commentary:coverage_scope:keyword matches to trial identifier and registry aliases; single-letter acronym variants require planned context in the same indexed chunk; unnamed references or other transcription variants may be absent","commentary:indexed_source_unreadable:podcast:episode_id:c6ac2a:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:scribe_unavailable:mcp:podcast:8bc5cd: diarized re-transcription failed; quotes use the discovery transcript.","commentary:held_out:mcp:podcast:83b3be@32095:32420,mcp:podcast:83b3be@29845:30165,mcp:podcast:83b3be@33121:34015: a claim leaves the object of Bex's stopping practice unresolved, although mcp:podcast:83b3be@29845:30165 asks specifically about systemic treatment after deferred nephrectomy and mcp:podcast:83b3be@33121:34015 elaborates on coming off therapy. The report repeats this artificial uncertainty in F5.","commentary:held_out:mcp:podcast:18f59f@38117:40100: Pompeo's reply about partial cytoreductive nephrectomy is absent from the inventory and its supporting quotations. He says publications exist in metastatic disease, but explicitly not in the residual-cystic-lesion scenario Korkes proposed.","commentary:held_out:mcp:podcast:8bc5cd@12405:15608: The connected cabozantinib/nivolumab discussion retains Pal's favorable response and quality-of-life rationale but omits his consequential toxicity-attribution difficulty and treatment-hold approach for overlapping diarrhea or hepatitis.","commentary:held_out:mcp:podcast:a24b45@16506:18303: The connected favorable-risk treatment decision omits the interlocutor's reasons for questioning upfront doublet therapy: possible progression delay for some patients, no demonstrated overall-survival improvement in the cited favorable-risk analyses, and additional toxicity and patient cost.","commentary:held_out:mcp:podcast:a24b45@18305:19478,mcp:podcast:a24b45@19815:20078: a claim retains Quinn's later, broader bottom-line wording, but neither its quotations nor another claim retain the earlier, more restrictive position: ipilimumab/nivolumab is an intermediate-/poor-risk option, yet Quinn would really only consider it for the highest-risk patients because of increased toxicity. Quinn also reports no statistically significant favorable-risk survival benefit in the preceding comparison.","commentary:held_out:mcp:podcast:a24b45@20080:20398: The unidentified interlocutor's selective exception for sarcomatoid pathology is absent: the speaker describes greater immune-therapy sensitivity and prefers nivolumab/ipilimumab if there are no contraindications.","commentary:held_out:mcp:podcast:83b3be@57226:57726: The inventory omits an explicit qualification relevant to the retained treatment-free discussion: an unidentified panelist opposes stopping what they call the nivolumab “adjuvant period” after ipilimumab/nivolumab in clear-cell renal cancer, including advanced disease, without strong evidence, which they say is lacking.","commentary:held_out:mcp:podcast:aa3641@30898:33804: The connected local-treatment alternative discussion omits Hall's practical trial-access condition: the study was changed to permit patients already receiving immunotherapy, creating a research option for some patients excluded from new-systemic-agent trials.","commentary:held_out:mcp:podcast:aa3641@30898:33804,mcp:podcast:aa3641@33806:34218: Hall's support for inexperienced renal-SBRT centers is absent: mandatory prospective expert plan review before treatment, with feedback and assistance, is described as a reassuring benefit of trial participation.","commentary:held_out:mcp:podcast:aa3641@34986:36473: Hall's answer supplies an omitted consequential limitation on the biomarker program: specific initiatives remain undecided pending grants and funding, although longitudinal blood banking is underway.","commentary:held_out:mcp:x_thread:1599067294948556802:be73b90c-fc18-476a-9ebb-9dc8288586a9@8146:8377: The radiation alternative discussion omits Zaorsky's treatment-hold opinion and its reason: TKIs should be held during radiotherapy because, in Zaorsky's characterization of cross-cancer experience, combining them has increased toxicity without improving survival."],"source_count":34,"unreadable_unit_ids":[]},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Sources were found by searching for the trial's name, registry number and known aliases. Discussion that refers to the trial without naming it may be missing.","For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.","11 points raised by the independent review are not yet resolved in this edition, such as a clinician view not yet captured as evidence or a qualifier to restore. The next refresh takes them up.","1 further source limit is recorded in the machine-readable scope of this record.","The 34 retained commentary sources are not a count of independent HCPs and do not establish the prevalence of any view.","Discussion located through trial identifiers and aliases may miss unnamed references or different transcription variants.","One additional podcast could not be accessed; another transcript lacked additional audio verification, increasing uncertainty about exact wording.","Several consequential panel views cannot be attributed to a named speaker. Rosters and nearby named comments do not resolve ownership.","The full SURTIME publication text was unavailable. The supplied abstract nevertheless reports the null 28-week progression-free-rate result and a favorable nominal secondary intention-to-treat OS comparison; differing commentary remains attributed to each speaker rather than reconciled into one statistical assessment.","Some relevant discussion of treatment stopping, systemic-regimen toxicity and cost, surgical exceptions, radiation-study access and support, and biomarker plans is not included in the available synthesis. The retained views should not be read as complete accounts of those decisions.","Some social posts are truncated or omit outcome definitions, comparators and selection criteria. Their numerical summaries should not be treated as complete study reports.","Cross-cancer, non-clear-cell, oligoprogressive and non-metastatic evidence appears only as explicitly limited context or alternatives; it does not establish effects in SURTIME's clinical population.","The separate Cytoshrink commentary concerns early SBRT added to nivolumab/ipilimumab. Its null one-year PFS account, responder-only ongoing-response observation, intervention-arm imbalance and forthcoming OS/quality-of-life follow-up do not resolve nephrectomy sequencing.","Source dates are publication or post dates unless the source explicitly supplies other timing; they do not prove a change of mind across discussions."]},"sources":{"cited_sources":{"by_channel":{"other":0,"podcast":10,"publication":0,"registry":0,"regulatory":0,"x_thread":21,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":32},"count":32,"evidence_window":{"end":"2026-10-02","start":"2022-07-26"},"retrieval_snapshot":"2026-10-08T00:55:41.743294Z","timeline":[{"count":1,"week":"2022-W30"},{"count":1,"week":"2022-W36"},{"count":2,"week":"2022-W42"},{"count":1,"week":"2022-W48"},{"count":1,"week":"2023-W10"},{"count":2,"week":"2023-W11"},{"count":1,"week":"2023-W21"},{"count":2,"week":"2023-W22"},{"count":1,"week":"2023-W30"},{"count":1,"week":"2023-W39"},{"count":1,"week":"2024-W04"},{"count":1,"week":"2024-W07"},{"count":1,"week":"2024-W11"},{"count":1,"week":"2024-W18"},{"count":1,"week":"2024-W21"},{"count":1,"week":"2024-W22"},{"count":1,"week":"2024-W31"},{"count":1,"week":"2024-W38"},{"count":2,"week":"2024-W48"},{"count":1,"week":"2025-W02"},{"count":1,"week":"2025-W05"},{"count":1,"week":"2025-W11"},{"count":2,"week":"2025-W23"},{"count":1,"week":"2025-W24"},{"count":1,"week":"2025-W29"},{"count":1,"week":"2025-W31"},{"count":1,"week":"2025-W34"},{"count":1,"week":"2025-W42"},{"count":1,"week":"2026-W10"},{"count":1,"week":"2026-W40"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT01099423:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT01099423:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:23228299","quote_policy":"short_quote_link_out"},{"id":"pubmed:24338498","quote_policy":"short_quote_link_out"},{"id":"pubmed:30543350","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:18f59f","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:45979f","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:6a6452","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:83b3be","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:8bc5cd","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:a24b45","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:a96485","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:aa3641","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:bef898","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:e1bc5f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1552019701156429824:6b42792f-ced9-4b2b-bf1d-663200928a6e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1568222797838655489:94ae1825-9cfb-4a90-a65c-afdd9e7f8788","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1569357496044892161:769aef57-6287-4fac-b769-6b40f54c75c6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1582967448579760128:f0ea78fc-0d91-48e1-afe4-2b2adeb7e6a6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1583045641873129472:5f8b8e58-7f83-45b1-b544-d9a6ba52176e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1599067294948556802:be73b90c-fc18-476a-9ebb-9dc8288586a9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1634963301938651137:4c3df37f-4fa1-400c-bd1a-6ccbc0e0e574","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1636519010274795520:d70e6763-99dc-484b-b155-671be0f60619","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1662819048009134082:7b22685e-c585-4070-ad6a-49f7fee40cd7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1665115876113145861:10a08912-c124-4b61-a4b1-37f234506d33","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1707747310833160301:b3539490-dab9-4ccb-b622-eec115cdca35","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1722992476938772838:3a6291b1-e8da-47dc-840d-ce886756377a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1750892632979718276:69305aab-eecd-4f4e-83c6-209995c0170f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797189702996422689:135a8325-c163-461f-b230-2faee69f2ff0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835673291102589410:874efdb6-da1c-431c-903b-ebe15a936e45","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1861406151524356383:12190016-2d4a-4d20-9582-f149cf917fc8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1861410569997144566:a6619119-34a4-49d0-8fb9-9073ad45dfbe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1877483537651143060:a25051f6-5282-4ecf-b6f3-9e82ebb52416","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1885647028539281807:48a1e82c-00f3-4211-a3c2-f40a32ad8ec7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929533295278051495:92462a2d-02e6-4b0c-9097-5ae2a7c26d47","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929540529307484633:6f74e497-214e-44b6-92f2-6a1ff1d8a588","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979479423167414695:78229f78-a99e-443c-85d1-e3dc37150b54","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2106089025635504287:2bf5f8c8-8062-49e8-ba67-d1551f883c04","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:b1u4hTm9G40","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"other":0,"podcast":10,"publication":0,"registry":0,"regulatory":0,"x_thread":23,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":34},"count":34,"evidence_window":{"end":"2026-10-02","start":"2022-07-26"},"retrieval_snapshot":"2026-10-08T00:55:41.743294Z","timeline":[{"count":1,"week":"2022-W30"},{"count":1,"week":"2022-W36"},{"count":1,"week":"2022-W37"},{"count":2,"week":"2022-W42"},{"count":1,"week":"2022-W48"},{"count":1,"week":"2023-W10"},{"count":2,"week":"2023-W11"},{"count":1,"week":"2023-W21"},{"count":2,"week":"2023-W22"},{"count":1,"week":"2023-W30"},{"count":1,"week":"2023-W39"},{"count":1,"week":"2023-W45"},{"count":1,"week":"2024-W04"},{"count":1,"week":"2024-W07"},{"count":1,"week":"2024-W11"},{"count":1,"week":"2024-W18"},{"count":1,"week":"2024-W21"},{"count":1,"week":"2024-W22"},{"count":1,"week":"2024-W31"},{"count":1,"week":"2024-W38"},{"count":2,"week":"2024-W48"},{"count":1,"week":"2025-W02"},{"count":1,"week":"2025-W05"},{"count":1,"week":"2025-W11"},{"count":2,"week":"2025-W23"},{"count":1,"week":"2025-W24"},{"count":1,"week":"2025-W29"},{"count":1,"week":"2025-W31"},{"count":1,"week":"2025-W34"},{"count":1,"week":"2025-W42"},{"count":1,"week":"2026-W10"},{"count":1,"week":"2026-W40"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: gene expression analysis","status":"unmapped"},{"reason":"Unmapped registry intervention: biologic sample preservation procedure","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Renal cell carcinoma","slug":"renal-cell-carcinoma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"SURTIME","aliases":["SURTIME","Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer","Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma"],"brief_title":"Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer","collaborators":["Wales Cancer Trials Unit","Canadian Urologic Oncology Group","Institute of Cancer Research, United Kingdom"],"conditions":["Kidney Cancer"],"enrollment":{"count":99,"type":"ACTUAL"},"excluded_lookalike_trials":{"reason":"No owner-reviewed lookalike exclusion list.","status":"not_set"},"interventions":[{"name":"timing of surgery","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"PROCEDURE"},{"name":"gene expression analysis","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"GENETIC"},{"name":"biologic sample preservation procedure","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"OTHER"},{"name":"laboratory biomarker analysis","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"OTHER"},{"name":"therapeutic conventional surgery","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"PROCEDURE"}],"nct_id":"NCT01099423","official_title":"Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma","overall_status":"UNKNOWN","phase":["PHASE3"],"primary_completion_date":{"date":"2016-04","type":"ACTUAL"},"primary_endpoints":[{"measure":"Overall progression-free survival"}],"registry_last_updated":"2017-02-08","registry_url":"https://clinicaltrials.gov/study/NCT01099423","short_name":"SURTIME","short_name_basis":"registry_acronym","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","start_date":{"date":"2010-04","type":"ACTUAL"},"study_design":"interventional, randomized, single group, phase3","study_ids":[{"id":"EORTC-30073","type":"sponsor_study_id"},{"id":"EU-21022","type":"other"},{"id":"PFIZER-EORTC-30073","type":"other"}],"study_type":"INTERVENTIONAL"}}}